Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-hodgkin's lymphoma

European Journal of Medical Research

Volumn 13, Issue 10, 2008, Pages 483-486

  Wasmuth, Jan Christian ^a   Fischer, H P ^a   Sauerbruch, T ^a   Dumoulin, F L ^a,b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Gemeinschaftskrankenhaus Bonn ^*  (Germany)

Author keywords

Chemotherapy; Hepatitis B; Liver failure; Reactivation

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PHENPROCOUMON; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; AUTOIMMUNE HEPATITIS; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; HEMOFILTRATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LEG THROMBOSIS; LIVER BIOPSY; LIVER FAILURE; LIVER FIBROSIS; LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NONHODGKIN LYMPHOMA; RELAPSE; SEPTIC SHOCK; VEIN OCCLUSION; VIRUS REACTIVATION; WATCHFUL WAITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER FAILURE, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; VIDARABINE;

EID: 56249093149     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991 Jan; 100(1): 182-8.
2. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006 Feb; 43(2): 209-20.
3. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, Johnson PJ. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004 Apr 5; 90(7): 1306-11.
4. Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK, Locarnini S, Liang R. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002 Sep; 36(3): 702-9.
5. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, Chan AT, Mok TS, Lee JJ, Leung TW, Zhong S, Johnson PJ. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004 Mar 1; 22(5): 927-34.
6. Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, Johnson PJ. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2004 Dec; 88(3): 209-15.
7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007 Feb; 45(2): 507-39.
8. Persico M, De Marino F, Russo GD, Morante A, Rotoli B, Torella R, De Renzo A. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood. 2002 Jan 15; 99(2): 724-5.
9. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood. 2002 Jul 15; 100(2): 391-6.
10. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol. 1995 Sep; 13(9): 2431-48.
11. Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, Persico M, Ciancia R, Salvatore F, Rotoli B. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. Haematologica. 2003 Nov; 88(11): 1296-303.